Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–15 of 15 results
Advanced filters: Author: Daniel Beene Clear advanced filters

  • Classification and risk-stratification for Acute Myeloid Leukemia (AML) at diagnosis are primarily based on cytogenetics and only a few gene mutations. Here, the authors study the genomic landscape of 3653 AML patients and characterize 16 non-overlapping molecular subgroups of clinical relevance for disease classification and risk prognostication.

    • Yanis Tazi
    • Juan E. Arango-Ossa
    • Elli Papaemmanuil
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-16

  • The RNA binding protein MUSASHI-2 (MSI2) is a potential therapeutic target for acute myeloid leukemia. Here the authors identify a small molecule inhibitor of MSI2 and characterize its effects in a murine leukemia model.

    • Gerard Minuesa
    • Steven K. Albanese
    • Michael G. Kharas
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-15

  • The authors provide preclinical testing of a CSFR-1 inhibitor in proneural glioma models. The compound targets macrophages in the tumor microenvironment rather than tumor cells themselves and is shown to portend considerable antitumor effects. Its activity relies on re-education of tumor-associated macrophages without affecting their survival, reverting their tumor-promoting phenotype. Moreover, gene signatures capturing the tumorigenic features of macrophages can predict survival in human patients with glioma, underscoring the potential relevance of this strategy as a glioma therapy.

    • Stephanie M Pyonteck
    • Leila Akkari
    • Johanna A Joyce
    Research
    Nature Medicine
    Volume: 19, P: 1264-1272

  • Patients with solid cancers have high rates of clonal haematopoiesis associated with increased risk of secondary leukemias. Here, by using peripheral blood sequencing data from patients with solid non-hematologic cancer, the authors profile the landscape of mosaic chromosomal alterations and gene mutations, defining patients at high risk of leukemia progression.

    • Teng Gao
    • Ryan Ptashkin
    • Elli Papaemmanuil
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-11

  • Genetic variants associated with susceptibility to pancreatic cancer have been identified using genome wide association studies (GWAS). Here, the authors combine data from over 9000 patients and perform a meta-analysis to identify five novel loci linked to pancreatic cancer.

    • Alison P. Klein
    • Brian M. Wolpin
    • Laufey T. Amundadottir
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-11

  • Molecular simulations reveal the self-assembly of small molecules into nanoparticle drug carriers. Targeting of colon and liver cancer cells by the nanoparticles via kinase inhibitors is employed in anti-tumour therapy in vivo.

    • Yosi Shamay
    • Janki Shah
    • Daniel A. Heller
    Research
    Nature Materials
    Volume: 17, P: 361-368

  • Environmental exposures shape patterns of selection for mutations in clonal hematopoiesis. Cancer therapies promote the growth of clones with mutations that are strongly enriched in treatment-related myeloid neoplasms.

    • Kelly L. Bolton
    • Ryan N. Ptashkin
    • Elli Papaemmanuil
    Research
    Nature Genetics
    Volume: 52, P: 1219-1226

  • Radionuclides that emit alpha particles (charged helium nuclei) are currently used clinically to treat cancers including prostate cancer. Here, the authors combine a humanized antibody to an alpha particle emitter, specifically to target a downstream effector of the androgen receptor and create a feed forward loop that increases the therapeutic efficacy.

    • Michael R. McDevitt
    • Daniel L. J. Thorek
    • David Ulmert
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-11

  • Recovery of the developing cerebellum after depletion of granule cells, the most plentiful neuron population, depends on adaptive reprogramming of neural progenitors to a new fate and a powerful cell–cell communication system that ensures re-establishment of the correct proportions of different cerebellar cell types and normal circuit formation.

    • Alexandre Wojcinski
    • Andrew K Lawton
    • Alexandra L Joyner
    Research
    Nature Neuroscience
    Volume: 20, P: 1361-1370

  • The epidermal growth factor receptor (EGFR) signalling is regulated at multiple levels. Here the authors show that the importin RanBP6 acts as a tumor suppressor in Glioblastoma and  regulates EGFR signalling through promoting translocation of STAT3 to the nuclei and repressing EGFR transcription.

    • Barbara Oldrini
    • Wan-Ying Hsieh
    • Ingo K. Mellinghoff
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-12

  • Precision medicine identifies the optimal treatment strategy for an individual patient. Such personalized therapies can be greatly improved by targeted drug delivery approaches. This Review investigates the integration of targeted drugs, in particular, kinase inhibitors, with targeted drug delivery systems.

    • Mandana T. Manzari
    • Yosi Shamay
    • Daniel A. Heller
    Reviews
    Nature Reviews Materials
    Volume: 6, P: 351-370